As Viatris seeks growth in eye care, its Ocuphire-partnered dilation drop Ryzumvi wins FDA nod
Fierce Pharma
SEPTEMBER 27, 2023
The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The partners plan to make Ryzumvi available in the U.S.
Let's personalize your content